COVID-19 Coagulopathy

被引:0
|
作者
Rettew, Andrew [1 ]
Garrahy, Ian [1 ]
Rahimian, Shoja [1 ]
Brown, Rebecca [1 ]
Sangha, Navdeep [1 ]
机构
[1] Reading Hosp, Tower Hlth Syst, W Reading, PA 19611 USA
来源
LIFE-BASEL | 2024年 / 14卷 / 08期
关键词
coagulopathy; SARS-CoV-2; vasculopathy; OPEN-LABEL; THROMBOSIS; HOSPITALIZATION; ANTICOAGULATION; COMPLICATIONS; COAGULATION; MULTICENTER; CELLS; RISK;
D O I
10.3390/life14080953
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as "long COVID". Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] COVID-19 associated coagulopathy and thrombosis in cancer
    Levi, Marcel
    van Es, Nick
    THROMBOSIS RESEARCH, 2022, 213 : S72 - S76
  • [32] COVID-19 Related Coagulopathy: A Distinct Entity?
    Marchandot, Benjamin
    Sattler, Laurent
    Jesel, Laurence
    Matsushita, Kensuke
    Schini-Kerth, Valerie
    Grunebaum, Lelia
    Morel, Olivier
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [33] COVID-19 Associated Coagulopathy and Thrombotic Complications
    Mezalek, Zoubida Tazi
    Khibri, Hajar
    Ammouri, Wafaa
    Bouaouad, Majdouline
    Haidour, Soukaina
    Harmouche, Hicham
    Maamar, Mouna
    Adnaoui, Mohamed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [34] Coagulation and anticoagulation in COVID-19
    Hadid, Tarik
    Kafri, Zyad
    Al-Katib, Ayad
    BLOOD REVIEWS, 2021, 47
  • [35] COVID-19 coagulopathy - what should we treat?
    Chowdary, Pratima
    EXPERIMENTAL PHYSIOLOGY, 2022, 107 (07) : 749 - 758
  • [36] Viral Coagulopathy in Patients With COVID-19: Treatment and Care
    Kipshidze, Nickolas
    Dangas, George
    White, Christopher J.
    Kipshidze, Nodar
    Siddiqui, Fakiha
    Lattimer, Christopher R.
    Carter, Charles A.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [37] Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19
    Dobesh, Paul P.
    Trujillo, Toby C.
    PHARMACOTHERAPY, 2020, 40 (11): : 1130 - 1151
  • [38] Coagulopathy in COVID-19: Manifestations and management
    Mucha, Simon R.
    Dugar, Siddharth
    McCrae, Keith
    Joseph, Douglas
    Bartholomew, John
    Sacha, Gretchen L.
    Militello, Michael
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (08) : 461 - 468
  • [39] Coagulopathy during COVID-19 infection: a brief review
    Cunningham, Robin M.
    Moore, Kyle L. Johnson
    Moore, Jacen S.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (03) : 655 - 666
  • [40] COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
    Miesbach, Wolfgang
    Makris, Michael
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26